| Literature DB >> 35628884 |
Joseph Lavelle1, Darragh Storan2,3, Varsha Eswara Murthy1, Noemi De Dominicis2, Hugh E Mulcahy2,3, Louise McHugh1.
Abstract
Psychological intervention targeting distress is now considered an integral component of inflammatory bowel disease (IBD) management. However, significant barriers to access exist which necessitate the development of effective, economic, and accessible brief and remote interventions. Acceptance and commitment therapy (ACT) is a therapy with demonstrated acceptability and a growing evidence base for the treatment of distress in IBD populations. The present paper trialled two brief ACT interventions via randomized multiple baseline designs. Study 1 trialled a single-session ACT intervention (delivered face-to-face and lasting approximately two hours) targeting stress and experiential avoidance, respectively. Participants were seven people with an IBD diagnosis who presented with moderate to extremely severe stress (five females, two males; M age = 39.57, SD = 5.74). The findings of study 1 indicate that a single-session ACT intervention represented an insufficient dosage to reduce stress and experiential avoidance. Study 2 investigated a brief telehealth ACT intervention (delivered via a video conferencing platform and lasting approximately four hours) targeting stress and increased psychological flexibility. Participants (N = 12 people with an IBD diagnosis and mild to extremely severe stress) completed baselines lasting from 21 to 66 days before receiving a two-session ACT telehealth intervention supplemented by a workbook and phone consultation. Approximately half of participants experienced reduced stress, increased engagement in valued action, and increased functioning. Despite shortcomings such as missing data and the context of COVID-19, the present findings suggest that brief ACT interventions in this population may be effective and economic, though further research and replications are necessary.Entities:
Keywords: acceptance and commitment therapy (ACT); brief interventions; inflammatory bowel disease (IBD)
Year: 2022 PMID: 35628884 PMCID: PMC9145285 DOI: 10.3390/jcm11102757
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Participant gender, IBD diagnosis, and DASS-measured stress at study commencement.
| Participant ID | Gender | IBD Diagnosis | DASS-21 Stress | Comorbid Diagnoses | Medical/Surgical Treatment | Last IBD Flare |
|---|---|---|---|---|---|---|
| 1 | Female | Crohn’s Disease | Severe | No | Medicine only 1 | 09/2019 |
| 4 | Female | Ulcerative Colitis | Moderate | No | Medicine only | 10/2019 (ongoing) 2 |
| 5 | Male | Ulcerative Colitis | Severe | No | Medicine only | 01/2018 |
| 6 | Male | Ulcerative Colitis | Moderate | No | Medicine only | 10/2019 (ongoing) |
| 7 | Female | Ulcerative Colitis | Moderate | IBS | Medicine only | 06/2019 |
| 8 | Female | Crohn’s Disease | Extreme | No | Medicine only | 08/2019 (ongoing) |
| 10 | Female | Crohn’s Disease | Severe | No | Medicine only | 07/2019 |
Note: 1 Participant received medical intervention (typically steroidal or biologic treatments) to manage IBD but had not at that time received surgical intervention. 2 Participant’s disease flare was ongoing during their participation in the study (October–December 2019).
Figure A1Study 1 participant flowchart.
Summary of single-session ACT intervention protocol.
| Phase | Aims | Exercise |
|---|---|---|
| Psychoeducation (10 min) | To introduce the link between stress and disease activity in IBD |
Description of stress and IBD |
| Creative hopelessness (15 min) | To introduce the unworkability of control strategies |
Polygraph metaphor |
|
Attempts and evaluations worksheet | ||
| Defusion (20 min) | To notice thoughts as barriers to action |
Content on cards |
|
Taking your mind for a walk | ||
|
I’m having the thought that… | ||
| Acceptance (15 min) | To develop willingness to experience internal events (such as stress) |
Physicalizing mindfulness exercise |
| Values (20 min) | To clarify personally meaningful values for the participant |
Values cards sort |
| Committed action (20 min) | To encourage workable behaviour change |
Matrix |
| Self-compassion (20 min) | To promote self-compassion |
Compassionate hand |
Figure 1SCED data for all participants on daily single measures of stress (left) and EA (right). Participant data are ordered via the order in which they received the intervention. Vertical dotted lines denote the data point at which the intervention was delivered. Shading denotes the one median absolute deviation from the median. Dashed horizontal lines denote the median while solid lines denote within-phase OLS regression trend lines.
SCED quantitative analyses summary for stress and experiential avoidance.
| Participant | Stress | EA | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Trend | Median |
| Ruscio’s A | Hedges | Trend | Median |
| Ruscio’s A | Hedges | |
| 1 | 0.01 | 2.0 | 0.0028 | 0.733 | 0.85 | 0.00 | 2.0 | 0.0012 | 0.740 | 0.90 |
| 4 | −0.01 | 0.0 | 0.4195 | 0.561 | 0.25 | 0.00 | 0.0 | 0.7940 | 0.479 | −0.09 |
| 5 | −0.50 | 0.0 | 0.7964 | 0.520 | −0.09 | −0.56 | 1.0 | 0.4801 | 0.583 | 0.21 |
| 6 | 0.23 | −1.5 | 0.0175 | 0.328 | −0.68 | 0.05 | 0.0 | 0.8577 | 0.492 | −0.06 |
| 7 | −0.29 | 0.5 | 0.4135 | 0.581 | 0.25 | −0.20 | 0.0 | 0.0442 | 0.470 | −0.60 |
| 8 | 0.48 | −1.0 | 0.6147 | 0.423 | −0.15 | 0.31 | −1.0 | 0.0003 | 0.230 | −1.13 |
| 10 | −0.12 | −2.0 | 0.2948 | 0.429 | −0.28 | −0.06 | −1.5 | 0.0107 | 0.295 | −0.69 |
Note: Trend denotes OLS regression trend during phase A (i.e., before intervention); median denotes the median difference between phases.
DASS-21 measured depression, anxiety, and stress at pre- and post-study.
| Participant ID | Time 1 | Time 2 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression | Anxiety | Stress | Depression | Anxiety | Stress | |||||||
| 1 | Moderate | 20 | Moderate | 14 | Severe | 30 | Extreme | 30 | Extreme | 26 | Extreme | 34 |
| 4 | Mild | 10 | Extreme | 22 | Moderate | 24 | - | - | - | - | - | - |
| 5 | Normal | 2 | Moderate | 12 | Severe | 32 | - | - | - | - | - | - |
| 6 | Normal | 2 | Normal | 4 | Moderate | 24 | Normal | 2 | Moderate | 12 | Moderate | 20 |
| 7 | Normal | 8 | Severe | 18 | Moderate | 22 | Normal | 0 | Normal | 4 ** | Normal | 10 ** |
| 8 | Moderate | 18 | Extreme | 32 | Extreme | 38 | Normal | 6 ** | Mild | 10 ** | Mild | 16 * |
| 10 | Moderate | 14 | Mild | 8 | Severe | 32 | Moderate | 18 | Normal | 2 | Mild | 18 * |
Note: Severity bands are derived from the DASS-21 manual and appear to the left of the participants’ scores [62]. Extreme denotes a severity band of extremely severe. * Denotes that reliable change was observed; ** denotes that both reliable and clinically significant change were observed.
Participant AAQ-II scores at times one and two.
| Participant ID | Time 1 AAQ-II | Time 2 AAQ-II | Change |
|---|---|---|---|
| 1 | 29 | 31 | +2 |
| 4 | 25 | ||
| 5 | 25 | ||
| 6 | 28 | 22 | −6 |
| 7 | 19 | 17 | −2 |
| 8 | 26 | 23 | −3 |
| 10 | 44 | 41 | −3 |
Participant gender, IBD diagnosis, and DASS-measured stress at screening.
| Participant ID | Gender | IBD Diagnosis | DASS-21 Stress at Screening | Comorbid Diagnoses | Medical/Surgical Treatment | Most Recent Disease Flare |
|---|---|---|---|---|---|---|
| 1 | Female | Indeterminate Colitis | Severe | No | Medicine only 1 | 05/2021 (Ongoing) 2 |
| 2 | Female | Ulcerative Colitis | Severe | No | Medicine only | 02/2021 |
| 3 | Female | Crohn’s Disease | Extreme | No | Medicine only | 04/2021 (Ongoing) |
| 4 | Female | Crohn’s Disease | Moderate | No | Medicine only | 01/2021 (ongoing) |
| 5 | Female | Crohn’s Disease | Mild | No | Medicine only | 02/2020 |
| 7 | Female | Crohn’s Disease | Extreme | No | Medicine only | 11/2020 |
| 8 | Female | Ulcerative Colitis | Moderate | Diabetes (Type 1) | Medicine only | 01/2021 |
| 9 | Male | Ulcerative Colitis | Moderate | No | Medicine only | 02/2020 |
| 11 | Male | Ulcerative Colitis | Mild | No | Medicine only | 2018 |
| 12 | Male | Indeterminate Colitis | Severe | No | Medicine only | 02/2021 |
| 13 | Female | Ulcerative Colitis | Severe | No | Medicine only | 09/2020 |
| 15 | Female | Crohn’s Disease | Severe | Gastritis; Diverticulosis | Medicine only | 07/2018 |
Note: 1 Participant received medical intervention (typically steroidal or biologic therapies) to manage IBD but had not at that time received surgical intervention (e.g., resection). 2 Participant’s disease flare was ongoing during their participation in the study (May–August 2021).
Figure A2Study 2 participant flowchart.
Two-session telehealth ACT intervention protocol.
| Session | Phase | Aims | Exercise |
|---|---|---|---|
| 1 | Introduction and psychoeducation (10 min) | To introduce the structure of intervention and the link between stress and disease activity in IBD |
Description of stress and IBD |
| Case conceptualization (35 min) | To gather information and conduct case formulization |
Focusing questions (FACT) | |
|
Attempts and evaluations worksheet | |||
| Creative hopelessness (15 min) | To further elaborate on control as the problem |
Polygraph metaphor | |
| Defusion (20 min) | To notice thoughts as barriers to action |
Content on cards | |
|
Taking your mind for a walk | |||
|
I’m having the thought that… | |||
| Acceptance (15 min) | To develop willingness to experience internal events |
Physicalizing mindfulness exercise | |
| Committed action and homework (10 min) | To set a SMART goal based on what has been identified as important via focusing questions and assign homework | ||
| 2 | Check-in (5 min) | To check on the progress of the SMART goal set at end of session one and review homework | |
| Intention setting/grounding exercise (10 min) | To promote present-moment awareness and promote awareness of toward and away moves in vivo | ||
| Review of previous session (10 min) | To re-cap on processes introduced in previous session and present information from session one in an ACT-consistent way |
Matrix | |
| Self-compassion (20 min) | To promote self-compassion |
Compassionate hand | |
| Values (20 min) | To identify and clarify values that are personally meaningful to the participant |
Values clarification worksheet | |
| Committed action (20 min) | To encourage workable behaviour change |
SMART Goal Setting worksheet | |
| Homework (5 min) | To set homework and arrange a time for phone follow-up |
Missing data per participant on daily measures of stress and PF.
| ID | Total | Phase A | Phase B | |||||
|---|---|---|---|---|---|---|---|---|
| Total Missed Sessions | Percentage Missing | Missed Sessions | Total Sessions | Missing Percent | Missed Sessions | Total Sessions | Missing Percent | |
| 1 | 34 | 33.70% | 1 | 37 | 02.70% | 33 | 64 | 51.56% |
| 2 | 1 | 01.00% | 0 | 23 | 00.00% | 1 | 78 | 01.28% |
| 3 | 8 | 07.90% | 6 | 50 | 12.00% | 2 | 51 | 03.92% |
| 4 | 30 | 29.07% | 0 | 30 | 00.00% | 30 | 71 | 42.25% |
| 5 | 34 | 33.70% | 21 | 66 | 31.80% | 13 | 35 | 37.14% |
| 7 | 16 | 15.80% | 9 | 63 | 14.28% | 7 | 38 | 18.42% |
| 8 | 2 | 01.90% | 1 | 49 | 02.04% | 1 | 52 | 01.92% |
| 9 | 0 | 00.00% | 0 | 49 | 00.00% | 0 | 52 | 00.00% |
| 11 | 2 | 01.90% | 0 | 28 | 00.00% | 2 | 83 | 02.41% |
| 12 | 35 | 34.70% | 4 | 58 | 06.90% | 31 | 43 | 72.09% |
| 13 | 26 | 25.70% | 2 | 21 | 09.52% | 24 | 80 | 30.00% |
| 15 | 1 | 00.90% | 1 | 56 | 01.79% | 0 | 45 | 00.00% |
Note: Sessions and missed sessions denote daily stress and PF recording sessions that were missed by the participant.
Treatment adherence and protocol compliance.
| ID | Adherence Score (0–11) | Session 1 | Session 2 | Phone Consultation | DNA | Rescheduled Sessions | Interventionist | Randomized Order | Actual Order |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 | Yes | Yes | Yes | 1 | 0 | Third | 6 | 5 |
| 2 | 7 | Yes | Yes | Yes | 0 | 0 | First | 3 | 2 |
| 3 | - | Yes | Yes | Yes | 0 | 3 | Third | 4 | 8 |
| 4 | - | Yes | Yes | Yes | 1 | 1 | First | 5 | 4 |
| 5 | - | Yes | No | No | 0 | 1 | First | 12 | 12 |
| 7 | 3 | Yes | No | No | 2 | 0 | Third | 10 | 11 |
| 8 | 1 | Yes | Yes | Yes | 0 | 0 | First | 7 | 6 |
| 9 | 2 | Yes | Yes | Yes | 0 | 0 | Third | 9 | 7 |
| 11 | - | Yes | Yes | Yes | 2 | 0 | First | 1 | 3 |
| 12 | - | Yes | Yes | Yes | 1 | 0 | First | 11 | 10 |
| 13 | 8 | Yes | Yes | Yes | 0 | 0 | First | 2 | 1 |
| 15 | 3 | Yes | Yes | Yes | 0 | 1 | First | 8 | 9 |
Note: DNA denotes that the participant missed an intervention session without giving prior notification. Interventionist denotes which author (first or third) delivered intervention components.
Figure A3SCED data for all study 2 participants on daily measure of stress. Note: Participant data are ordered via the order in which they received the intervention. Vertical dotted lines denote the data point at which the intervention was delivered. Shading denotes the one median absolute deviation from the median. Dashed horizontal lines denote the median while solid lines denote within-phase OLS regression trend lines.
Figure A4SCED data for all study 2 participants on daily measure of openness to experience. Note: Participant data are ordered via the order in which they received the intervention. Vertical dotted lines denote the data point at which the intervention was delivered. Shading denotes the one median absolute deviation from the median. Dashed horizontal lines denote the median while solid lines denote within-phase OLS regression trend lines.
Figure A5SCED data for all study 2 participants on daily measure of awareness. Note: Participant data are ordered via the order in which they received the intervention. Vertical dotted lines denote the data point at which the intervention was delivered. Shading denotes the one median absolute deviation from the median. Dashed horizontal lines denote the median while solid lines denote within-phase OLS regression trend lines.
Figure A6SCED data for all participants on daily measure of valued action. Note: Participant data are ordered via the order in which they received the intervention. Vertical dotted lines denote the data point at which the intervention was delivered. Shading denotes the one median absolute deviation from the median. Dashed horizontal lines denote the median while solid lines denote within-phase OLS regression trend lines.
Quantitative analyses summaries for stress and openness to experience.
| Participant | Stress | Openness | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Trend | Median |
| Ruscio’s A | Hedges | Trend | Median |
| Ruscio’s A | Hedges | |
| 1 | 0.33 * | 1.0 | 0.9391 | 0.505 | −0.02 | −0.05 | 2.0 | 0.0037 | 0.748 | 0.74 |
| 2 | 0.09 | −2.0 | 0.1472 | 0.399 | −0.36 | −0.42 * | 1.0 | 0.2742 | 0.598 | 0.26 |
| 3 | −0.58 * | −1.0 | 0.0034 | 0.347 | −0.63 | −0.55 * | −1.0 | 0.0056 | 0.361 | −0.59 |
| 4 | 0.15 | −4.0 | 0.0001 | 0.207 | −1.16 | −0.22 | −4.0 | <0.0001 | 0.139 | −1.63 |
| 5 | −0.27 | 0.0 | 0.9410 | 0.523 | −0.03 | 0.21 | 3.0 | <0.0001 | 0.820 | 1.35 |
| 7 | −0.26 | −1.0 | 0.0070 | 0.322 | −0.63 | −0.18 | −1.0 | 0.0174 | 0.333 | −0.55 |
| 8 | −0.65 * | 0.0 | 0.0001 | 0.344 | −0.85 | 0.22 | 6.0 | <0.0001 | 0.823 | 1.79 |
| 9 | −0.50 * | −2.0 | 0.0001 | 0.264 | −0.95 | 0.31 * | 1.0 | <0.0001 | 0.878 | 1.17 |
| 11 | −0.15 | 0.0 | 0.1150 | 0.409 | −0.37 | −0.34 * | −1.0 | <0.0001 | 0.263 | −1.12 |
| 12 | −0.11 | 0.0 | 0.0828 | 0.358 | −0.57 | 0.00 | 1.0 | 0.1680 | 0.660 | 0.45 |
| 13 | 0.42 * | 0.0 | 0.7891 | 0.485 | −0.08 | 0.01 | 0.5 | 0.2573 | 0.580 | 0.31 |
| 15 | 0.21 | −2.0 | 0.0001 | 0.159 | −1.36 | 0.08 | 2.0 | <0.0001 | 0.848 | 1.40 |
Note: Trend denotes OLS regression trend during phase A (i.e., before intervention); median denotes the median difference between phases. * denotes baseline trends of ±0.3.
Quantitative analyses summaries for awareness and valued action.
| Participant | Stress | Openness | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Trend | Median |
| Ruscio’s A | Hedges | Trend | Median |
| Ruscio’s A | Hedges | |
| 1 | −0.29 | 2.0 | <0.0001 | 0.842 | 1.01 | 0.00 | 1.0 | 0.0031 | 0.691 | 0.75 |
| 2 | −0.24 | 1.0 | 0.1378 | 0.612 | 0.36 | −0.34 * | 0.0 | 0.6686 | 0.511 | 0.11 |
| 3 | −0.11 | 0.0 | 0.7678 | 0.476 | −0.08 | 0.02 | 0.0 | 0.9389 | 0.472 | −0.02 |
| 4 | 0.02 | −1.5 | 0.0006 | 0.252 | −0.91 | 0.34 * | 0.0 | 0.4306 | 0.448 | −0.20 |
| 5 | 0.34 * | 3.0 | 0.0012 | 0.719 | 0.87 | 0.06 | 1.0 | 0.0350 | 0.641 | 0.56 |
| 7 | −0.38 * | −1.0 | 0.0052 | 0.310 | −0.64 | −0.52 * | 0.0 | 0.8516 | 0.495 | 0.05 |
| 8 | 0.00 * | 0.0 | - | - | - | 0.22 | 0.0 | 0.0486 | 0.542 | 0.43 |
| 9 | 0.65 * | 1.0 | <0.0001 | 0.843 | 1.21 | 0.67 * | 1.0 | 0.0018 | 0.666 | 0.66 |
| 11 | −0.20 | 1.0 | <0.0001 | 0.922 | 3.04 | −0.09 | 0.0 | 0.2859 | 0.482 | −0.36 |
| 12 | 0.21 | 0.0 | 0.6358 | 0.548 | 0.17 | 0.21 | 2.5 | 0.0043 | 0.767 | 0.95 |
| 13 | 0.43 * | 1.0 | <0.0001 | 0.786 | 1.14 | 0.09 | 1.0 | <0.0001 | 0.870 | 1.62 |
| 15 | 0.12 | 3.0 | <0.0001 | 0.880 | 1.67 | 0.12 | 3.0 | <0.0001 | 0.887 | 1.67 |
Note: Trend denotes OLS regression trend during phase A (i.e., before intervention); median denotes the median difference between phases. It was not possible to compute some test statistics via the R SCED package for participant 8 due to a complete lack of variability in their awareness data. * denotes baseline trends of ±0.3.
DASS-21 measured depression, anxiety, and stress at pre- and post-study.
| ID | Stress | Depression | Anxiety | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time 1 | Time 2 | Time 1 | Time 2 | Time 1 | Time 2 | |||||||
| 1 | 30 | Severe | * 18 | Mild | 16 | Moderate | 20 | Moderate | 20 | Extreme | 14 | Moderate |
| 2 | 36 | Extreme | * 20 | Moderate | 20 | Moderate | 12 | Mild | 30 | Extreme | * 14 | Moderate |
| 3 | 24 | Moderate | 20 | Moderate | 28 | Extreme | ||||||
| 4 | 16 | Mild | 8 | Normal | 16 | Severe | ||||||
| 5 | 24 | Moderate | 4 | Normal | 2 | Normal | ||||||
| 7 | 24 | Moderate | 32 | Severe | 10 | Mild | 14 | Moderate | 14 | Moderate | 20 | Extreme |
| 8 | 0 | Normal | 0 | Normal | 0 | Normal | 0 | Normal | 0 | Normal | 0 | Normal |
| 9 | 12 | Normal | 6 | Normal | 8 | Normal | 0 | Normal | 4 | Normal | 0 | Normal |
| 11 | 10 | Normal | 0 | Normal | 4 | Normal | ||||||
| 12 | 22 | Moderate | 30 | Extreme | 10 | Moderate | ||||||
| 13 | 24 | Moderate | 24 | Moderate | 18 | Moderate | 12 | Mild | 2 | Normal | 6 | Normal |
| 15 | 22 | Moderate | ** 8 | Normal | 16 | Moderate | 6 | Normal | 6 | Normal | 2 | Normal |
Note: Severity bands are derived from the DASS-21 manual and appear to the right of the participants’ scores [62]. Extreme denotes a severity band of extremely severe. * Denotes that reliable change was observed; ** denotes that both reliable and clinically significant change were observed.
CompACT-measured PF and CSS COVID stress pre- and post-study.
| ID | OE | Change | BA | Change | VA | Change | CompACT Total | Change | CSS Total | Change | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 | T2 | ||||||
| 1 | 7 | 12 | +5 | 2 | 7 | +5 | 37 | 34 | −3 | 46 | 53 | +7 | 40 | 8 | −32 |
| 2 | 26 | 27 | +1 | 7 | 8 | +1 | 27 | 24 | −3 | 60 | 59 | −1 | 85 | 40 | −45 |
| 3 | 17 | 13 | 38 | 68 | 27 | ||||||||||
| 4 | 41 | 22 | 3 | 66 | 26 | ||||||||||
| 5 | 29 | 22 | 34 | 85 | 29 | ||||||||||
| 7 | 15 | 22 | +7 | 7 | 1 | -6 | 25 | 23 | −2 | 47 | 46 | −1 | 17 | 28 | +11 |
| 8 | 39 | 49 | +10 | 22 | 23 | +1 | 42 | 47 | +5 | 103 | 119 | +16 | 6 | 4 | −2 |
| 9 | 31 | 29 | −2 | 10 | 10 | 0 | 40 | 46 | +6 | 81 | 85 | +4 | 33 | 16 | −17 |
| 11 | 27 | 24 | 32 | 83 | 7 | ||||||||||
| 12 | 15 | 9 | 25 | 49 | 35 | ||||||||||
| 13 | 30 | 23 | −7 | 2 | 0 | −2 | 20 | 17 | +3 | 52 | 40 | −12 | 14 | 0 | −14 |
| 15 | 26 | 30 | +4 | 13 | 15 | +2 | 32 | 37 | +5 | 71 | 82 | +11 | 18 | 5 | −13 |
Note: Increased CompACT subscale and total scores represent improved PF. Reduced scores of CSS denote reduced COVID-19-related stress.